RO7046015
Sponsors
F. Hoffmann-La Roche AG, Universitaetsklinikum Tuebingen AöR, Hoffmann-La Roche
Conditions
Early Idiopathic Parkinson’s disease (PD)Early Parkinson's diseaseEarly-Stage Parkinson’s Disease (PD)PARKINSON’S DISEASEParkinson's Disease
Phase 2
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
Active, not recruitingNCT03100149
Start: 2017-06-27End: 2031-12-01Updated: 2026-09-11
A Randomized, Double-Blind, Placebo-controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants with Early Parkinson’s Disease with A 11 Year All-Participants-on-Treatment Extension (PASADENA)
RecruitingCTIS2023-504472-24-00
Start: 2024-03-19Target: 238Updated: 2025-12-22
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease
Active, not recruitingCTIS2023-507132-21-00
Start: 2021-05-11Target: 398Updated: 2025-10-09
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
Not yet recruitingCTIS2024-513496-40-00
Target: 88Updated: 2026-06-19